TABLE 3.
Interaction between big endothelin-1 and diabetes in the prognosis of MACEs and secondary end points.
| Wald chi-square value* | P-value* | Wald chi-square value** | P-value** | |
| MACE | ||||
| Big ET-1 | 3.58 | 0.058 | 4.56 | 0.103 |
| Diabetes | 8.46 | 0.004 | 1.95 | 0.163 |
| Big ET-1 × Diabetes | 13.07 | <0.0001 | 9.61 | 0.008 |
| Age | 3.53 | 0.06 | 3.61 | 0.057 |
| Sex | 5.35 | 0.021 | 4.87 | 0.027 |
| BNP | 5.28 | 0.022 | 6.76 | 0.009 |
| Diameter stenosis rate | 1.83 | 0.177 | 1.63 | 0.201 |
| Thyroid disease | 4.53 | 0.033 | 4.36 | 0.037 |
| Secondary endpoints | ||||
| Big ET-1 | 2.93 | 0.087 | 4.86 | 0.088 |
| Diabetes | 6.23 | 0.013 | 1.4 | 0.236 |
| Big ET-1 × Diabetes | 12.55 | <0.0001 | 8.82 | 0.012 |
| Age | 1.07 | 0.302 | 1.16 | 0.282 |
| Sex | 3.1 | 0.078 | 2.85 | 0.092 |
| BNP | 5.71 | 0.017 | 7.48 | 0.006 |
| Diameter stenosis rate | 6.12 | 0.013 | 5.78 | 0.016 |
*Big endothelin-1 (ET-1) as a continuous variable. **Big ET-1 as a categorical variable, age, sex, and variables found as independent predictors in the overall population were adjusted. Big ET-1 and B-type natriuretic peptide (BNP) were natural log-transformed.